These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 35196863)
1. Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION. Peterson BE; Harrington RA; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Lopes RD; Leonardi S; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL Circ Cardiovasc Interv; 2022 Mar; 15(3):e011069. PubMed ID: 35196863 [TBL] [Abstract][Full Text] [Related]
2. Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX. Cavender MA; Harrington RA; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Lopes RD; Leonardi S; Deliargyris EN; Prats J; Mahaffey KW; White HD; Bhatt DL; Circ Cardiovasc Interv; 2022 Jan; 15(1):e010390. PubMed ID: 34915723 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial. O'Donoghue ML; Bhatt DL; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Prats J; Liu T; Deliargyris EN; Mahaffey KW; White HD; Harrington RA; Circulation; 2016 Jan; 133(3):248-55. PubMed ID: 26762525 [TBL] [Abstract][Full Text] [Related]
4. The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. Gutierrez JA; Harrington RA; Blankenship JC; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Généreux P; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL; Eur Heart J; 2016 Apr; 37(14):1122-30. PubMed ID: 26400827 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. Abtan J; Steg PG; Stone GW; Mahaffey KW; Gibson CM; Hamm CW; Price MJ; Abnousi F; Prats J; Deliargyris EN; White HD; Harrington RA; Bhatt DL; JACC Cardiovasc Interv; 2016 Sep; 9(18):1905-13. PubMed ID: 27659566 [TBL] [Abstract][Full Text] [Related]
6. Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. Sawlani NN; Harrington RA; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL Circ Cardiovasc Interv; 2017 Jan; 10(1):. PubMed ID: 28039321 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials. Vaduganathan M; Harrington RA; Stone GW; Deliargyris EN; Steg PG; Gibson CM; Hamm CW; Price MJ; Menozzi A; Prats J; Elkin S; Mahaffey KW; White HD; Bhatt DL JAMA Cardiol; 2017 Feb; 2(2):127-135. PubMed ID: 27902833 [TBL] [Abstract][Full Text] [Related]
9. Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). Cavender MA; Bhatt DL; Stone GW; White HD; Steg PG; Gibson CM; Hamm CW; Price MJ; Leonardi S; Prats J; Deliargyris EN; Mahaffey KW; Harrington RA; Circulation; 2016 Sep; 134(10):723-33. PubMed ID: 27482008 [TBL] [Abstract][Full Text] [Related]
10. Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y Abtan J; Ducrocq G; Steg PG; Stone GW; Mahaffey KW; Gibson CM; Hamm CW; Price MJ; Prats J; Deliargyris EN; White HD; Harrington RA; Bhatt DL Circ Cardiovasc Interv; 2019 Mar; 12(3):e007445. PubMed ID: 30871355 [TBL] [Abstract][Full Text] [Related]
11. Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]). White HD; Bhatt DL; Gibson CM; Hamm CW; Mahaffey KW; Price MJ; Steg PG; Stone GW; Cortese B; Wilensky M; Deliargyris EN; Liu T; Prats J; Harrington RA JACC Cardiovasc Interv; 2015 Mar; 8(3):424-433. PubMed ID: 25703887 [TBL] [Abstract][Full Text] [Related]
12. Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. Vaduganathan M; Harrington RA; Stone GW; Deliargyris EN; Steg PG; Gibson CM; Hamm CW; Price MJ; Menozzi A; Prats J; Elkin S; Mahaffey KW; White HD; Bhatt DL; J Am Coll Cardiol; 2017 Jan; 69(2):176-185. PubMed ID: 28081827 [TBL] [Abstract][Full Text] [Related]
13. Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). Groves EM; Bhatt DL; Steg PG; Deliargyris EN; Stone GW; Gibson CM; Hamm CW; Mahaffey KW; White HD; Angiolillo DJ; Prats J; Harrington RA; Price MJ Circ Cardiovasc Interv; 2018 Apr; 11(4):e005635. PubMed ID: 29632238 [TBL] [Abstract][Full Text] [Related]
14. Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. Vaduganathan M; Harrington RA; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL Circ Cardiovasc Interv; 2016 Jun; 9(6):e003612. PubMed ID: 27313282 [TBL] [Abstract][Full Text] [Related]
15. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341 [TBL] [Abstract][Full Text] [Related]
16. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Steg PG; Bhatt DL; Hamm CW; Stone GW; Gibson CM; Mahaffey KW; Leonardi S; Liu T; Skerjanec S; Day JR; Iwaoka RS; Stuckey TD; Gogia HS; Gruberg L; French WJ; White HD; Harrington RA; Lancet; 2013 Dec; 382(9909):1981-92. PubMed ID: 24011551 [TBL] [Abstract][Full Text] [Related]
17. Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. Leonardi S; Mahaffey KW; White HD; Gibson CM; Stone GW; Steg GW; Hamm CW; Price MJ; Todd M; Dietrich M; Gallup D; Liu T; Skerjanec S; Harrington RA; Bhatt DL Am Heart J; 2012 May; 163(5):768-776.e2. PubMed ID: 22607853 [TBL] [Abstract][Full Text] [Related]
18. Effect of platelet inhibition with cangrelor during PCI on ischemic events. Bhatt DL; Stone GW; Mahaffey KW; Gibson CM; Steg PG; Hamm CW; Price MJ; Leonardi S; Gallup D; Bramucci E; Radke PW; Widimský P; Tousek F; Tauth J; Spriggs D; McLaurin BT; Angiolillo DJ; Généreux P; Liu T; Prats J; Todd M; Skerjanec S; White HD; Harrington RA; N Engl J Med; 2013 Apr; 368(14):1303-13. PubMed ID: 23473369 [TBL] [Abstract][Full Text] [Related]
19. Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials. Eisen A; Harrington RA; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL; Int J Cardiol; 2018 Jan; 250():49-55. PubMed ID: 29030140 [TBL] [Abstract][Full Text] [Related]
20. Platelet inhibition with cangrelor in patients undergoing PCI. Harrington RA; Stone GW; McNulty S; White HD; Lincoff AM; Gibson CM; Pollack CV; Montalescot G; Mahaffey KW; Kleiman NS; Goodman SG; Amine M; Angiolillo DJ; Becker RC; Chew DP; French WJ; Leisch F; Parikh KH; Skerjanec S; Bhatt DL N Engl J Med; 2009 Dec; 361(24):2318-29. PubMed ID: 19915221 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]